Beta Bionics (NASDAQ:BBNX) Stock Rating Upgraded by Barclays

Key Points

• Barclays upgraded Beta Bionics to “strong buy,” while analysts maintain a consensus “Moderate Buy” rating and an average price target of $23.50.
• BBNX shares opened at $17.43, down 3.6%, and remain highly volatile, with a 12-month range of $8.80 to $32.71. The company reported a quarterly loss of $0.53 per share, though it beat estimates by $0.09.
• Regulatory and litigation risks remain significant: investor lawsuits allege inadequate disclosure of FDA concerns involving the iLet system, while insiders have sold about 97,697 shares worth $1.9 million over the past quarter.

Beta Bionics (NASDAQ:BBNX - Get Free Report) was upgraded by Barclays to a "strong-buy" rating in a research report issued to clients and investors on Tuesday, Zacks reports.

A number of other equities analysts have also issued reports on BBNX. UBS Group reaffirmed a "buy" rating and set a $25.00 target price on shares of Beta Bionics in a research report on Tuesday, September 15th. Bank of America boosted their price objective on Beta Bionics from $18.00 to $20.00 and gave the company a "neutral" rating in a research report on Tuesday, September 15th. Weiss Ratings raised shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. Wall Street Zen upgraded Beta Bionics from a "sell" rating to a "hold" rating in a research note on Saturday, September 19th. Finally, Truist Financial boosted their target price on shares of Beta Bionics from $23.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Beta Bionics has an average rating of "Moderate Buy" and a consensus price target of $23.50.

Beta Bionics Stock Down 3.6%

Shares of Beta Bionics stock opened at $17.43 on Tuesday. The stock has a 50 day moving average price of $18.66 and a two-hundred day moving average price of $14.96. Beta Bionics has a 12-month low of $8.80 and a 12-month high of $32.71. The stock has a market capitalization of $784.18 million, a P/E ratio of -10.56 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Sell-side analysts anticipate that Beta Bionics will post -2.02 earnings per share for the current year.

Insider Activity at Beta Bionics

In related news, insider Mike Mensinger sold 2,650 shares of the firm's stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the transaction, the insider owned 177,390 shares in the company, valued at $3,902,580. This trade represents a 1.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christy Jones sold 6,430 shares of Beta Bionics stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total value of $147,890.00. Following the completion of the sale, the director owned 19,564 shares of the company's stock, valued at approximately $449,972. The trade was a 24.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 97,697 shares of company stock valued at $1,907,034 over the last quarter. 5.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BBNX. Squarepoint Ops LLC acquired a new stake in shares of Beta Bionics during the 2nd quarter worth approximately $2,524,000. Bank of America Corp DE acquired a new position in Beta Bionics in the second quarter valued at approximately $8,566,000. Man Group plc acquired a new position in Beta Bionics in the second quarter valued at approximately $419,000. Legal & General Group Plc bought a new position in Beta Bionics in the second quarter valued at approximately $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics during the 2nd quarter worth $172,000.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Several law firms reminded shareholders that November 3, 2026 is the deadline to seek appointment as lead plaintiff in a proposed class action covering investors who purchased BBNX shares from July 30, 2025, through February 24, 2026. The notices primarily solicit potential claimants and do not represent a new operational development. Rosen Law Firm deadline notice
• Negative Sentiment: Multiple firms, including Hagens Berman, Kaplan Fox, Rosen and others, say the lawsuit alleges Beta Bionics and certain executives minimized the significance of an FDA Form 483 and failed to adequately disclose regulatory concerns involving iLet. The allegations reportedly include more than 18,000 unreported complaints and preceded an FDA Warning Letter becoming public. The claims have not been proven. Hagens Berman Beta Bionics class-action alert
• Negative Sentiment: The legal coverage highlights the severity of the prior selloff: BBNX allegedly fell from a Class Period high near $31.99 to below $9 across several FDA-related disclosures. The continuing stream of law-firm announcements increases headline, litigation and reputational risk, helping explain the stock’s decline and volatility. Levi and Korsinsky investor alert

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company's dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person's body weight and meal announcements as key inputs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.